BIIB ▲ +1.5% - Biogen Inc. $BIIB - Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN Biogen rose 1.5% following publication of Phase 3 pediatric data for EMPAVELI in a peer-reviewed journal, demonstrating the drug reduced proteinuria and stabilized kidney function in adolescents with C3G or primary IC-MPGN. The positive clinical results support the therapeutic profile of the complement-targeted treatment in a younger patient population with rare kidney diseases. 17-SEP-2026 04:15 PM ET